Urate-lowering therapy and the risk of developing type 2 diabetes mellitus in patients with gout (results of a prospective study)
https://doi.org/10.14412/1996-7012-2023-5-73-78
Abstract
Objective: to analyze the association between medications intake and the development of type 2 diabetes mellitus (T2DM) in patients with gout.
Material and methods. The study included 444 patients with gout without T2DM. The median follow-up time was 5.9 [2.9; 8.7] years. The primary end point was the diagnosis of T2DM. At baseline, therapy was initiated or adjusted according to current guidelines. Medication use was recorded: allopurinol, febuxostat, diuretics, glucocorticoids (GC), canakinumab, for which the odds ratio (OR) of developing T2DM was calculated.
Results and discussion. T2DM occurred in 108 (24.3 %) patients enrolled in the study. 405 patients completed the study. 311 (76.7 %) patients were taking urate-lowering drugs: 263 (90.7 %) allopurinol, 48 (9.3 %) febuxostat. The mean dose of allopurinol was 153.4 ± 28.4 mg/day, and that of febuxostat was 91.6 ± 12.1 mg/day. During treatment with febuxostat, the probability of developing T2DM was lower: OR 0.433 (95 % confidence interval, CI 0.188–0.996; p = 0.044). When diuretics were used OR was 2.212 (95 % CI 1.303–3.753; p = 0.003), GC – 1.566 (95 % CI 1.003–2.445; p = 0.048).
Conclusion. Febuxostat use is associated with a lower likelihood of developing T2DM.
Supporting agencies: The investigation has not been sponsored
About the Authors
M. S. Eliseev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Maxim Sergeevich Eliseev
115522
34A, Kashirskoe Shosse
Moscow
O. V. Zhelyabina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522
34A, Kashirskoe Shosse
Moscow
References
1. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020 Jul;16(7):380-390. doi: 10.1038/s41584-020-0441-1.
2. Thottam GE, Krasnokutsky S, Pillinger MH. Gout and Metabolic Syndrome: a Tangled Web. Curr Rheumatol Rep. 2017 Aug 26;19(10):60. doi: 10.1007/s11926-017-0688-y.
3. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford). 2008 Oct;47(10):1567-70. doi: 10.1093/rheumatology/ken305. Epub 2008 Aug 18.
4. Tung YC, Lee SS, Tsai WC, et al. Association Between Gout and Incident Type 2 Diabetes Mellitus: A Retrospective Cohort Study. Am J Med. 2016 Nov;129(11):1219.e17-1219.e25. doi: 10.1016/j.amjmed.2016.06.041. Epub 2016 Jul 21.
5. Johnson RJ, Andrews P, Benner SA, Oliver W. Theodore E. Woodward award. The evolution of obesity: insights from the mid-Miocene. Trans Am Clin Climatol Assoc. 2010;121:295-305.
6. Johnson RJ, Stenvinkel P, Andrews P, et al. Fructose metabolism as a common evolutionary pathway of survival associated with climate change, food shortage and droughts. J Intern Med. 2020 Mar;287(3):252-262. doi: 10.1111/joim.12993. Epub 2019 Oct 31.
7. Zhelyabina OV, Eliseev MS. The development of type 2 diabetes mellitus with gout. Nauchno-prakticheskaya revmatologiya. 2021;59(5):599-607. (In Russ.)
8. Zhelyabina OV, Eliseev MS, Glukhova SI, et al. Risk factors for type 2 diabetes mellitus in patients with gout: results from a prospective study. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2022;16(1):52–59. (In Russ.) doi: 10.14412/1996-7012-2022-1-52-59.
9. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977 Apr;20(3):895-900. doi: 10.1002/art.1780200320.
10. Alberti G. A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1998–1999 International Diabetes Federation European Region. Exp Clin Endocrinol Diabetes. 1999;107(7):390-420.
11. Nasonov EL, editor. Revmatologiya: klinicheskie rekomendatsii. 2-e izd [Rheumatology: clinical guidelines. 2<sup>nd</sup> ed]. Moscow: GEOTAR-Media; 2011. 752 p.
12. Sluijs I, Holmes MV, van der Schouw YT, et al. A Mendelian Randomization Study of Circulating Uric Acid and Type 2 Diabetes. Diabetes. 2015 Aug;64(8):3028-36. doi: 10.2337/db14-0742. Epub 2015 Apr 27.
13. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001 Jul 18;286(3):327-34. doi: 10.1001/jama.286.3.327.
14. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006 Mar 9; 440(7081):237-41. doi: 10.1038/nature04516.
15. Choi S, Voskanian N, Ramos J, Nguyen KHY. Tophaceous Gout in the Pancreas: Case Reports and Review of the Literature. Case Rep Rheumatol. 2022 Jun 3;2022:3671627. doi: 10.1155/2022/3671627.
16. Toprover M, Shah B, Oh C, et al. Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study. Arthritis Res Ther. 2020 Jul 11;22(1):169. doi: 10.1186/s13075-020-02260-6.
17. Chikina MN, Eliseev MS, Zhelyabina OV. Practical application of national clinical guidelines for the management of gout (preliminary data). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2020;14(2):97-103. (In Russ.) doi: 10.14412/1996-7012-2020-2-97-103.
18. Meng J, Li Y, Yuan X, Lu Y. Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout. Rheumatol Int. 2017 Feb;37(2):299-303. doi: 10.1007/s00296-016-3612-2. Epub 2016 Nov 23.
19. Fang YJ, Chung YL, Lin CL, et al. Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study. Biomed Res Int. 2020 Jul 28;2020:6358954. doi: 10.1155/2020/6358954. eCollection 2020.
20. Lee S, So MW, Ahn E. Long-term adherence and persistence with febuxostat among male patients with gout in a routine clinical setting. Mod Rheumatol. 2019 Jul;29(4):662-668. doi: 10.1080/14397595.2018.1483293. Epub 2018 Nov 28.
21. Afshari M, Larijani B, Rezaie A, et al. Ineffectiveness of allopurinol in reduction of oxidative stress in diabetic patients; a randomized, double-blind placebo-controlled clinical trial. Biomed Pharmacother. 2004 Dec;58(10):546-50. doi: 10.1016/j.biopha.2004.09.012.
22. Chang HW, Lin YW, Lin MH, et al. Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus. PLoS One. 2019 Jan 7;14(1):e0210085. doi: 10.1371/journal.pone.0210085. eCollection 2019.
23. Zhelyabina OV, Eliseev MS, Glukhova SI, Nasonov EL. Factors influencing the development of type 2 diabetes mellitus in patients with gout (results of a long-term prospective study). Nauchno-prakticheskaya revmatologiya. 2022;60(3):374-380. (In Russ.)
24. Johnson RJ, Merriman T, Lanaspa MA. Causal or Noncausal Relationship of Uric Acid With Diabetes. Diabetes. 2015 Aug; 64(8):2720-2. doi: 10.2337/db15-0532.
25. Takir M, Kostek O, Ozkok A, et al. Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia. J Investig Med. 2015 Dec;63(8):924-9. doi: 10.1097/JIM.0000000000000242.
26. Eliseev MS, Zhelyabina OV, Mukagova MV, Nasonov EL. Clinical experience with the interleukin-1 blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopurinol is used. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015; 9(2):16-22. (In Russ.) doi: 10.14412/1996-7012-2015-2-16-22
27. Everett BM, Donath MY, Pradhan AD, et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. J Am Coll Cardiol. 2018 May 29; 71(21):2392-2401. doi: 10.1016/j.jacc.2018.03.002.
Review
For citations:
Eliseev MS, Zhelyabina OV. Urate-lowering therapy and the risk of developing type 2 diabetes mellitus in patients with gout (results of a prospective study). Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2023;17(5):73-78. (In Russ.) https://doi.org/10.14412/1996-7012-2023-5-73-78
Views:
426
Email this article 